Frederick Lane, MD
Colon & Rectal Surgery · Indianapolis, INNPI 1376507103
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $3,185 of the $4,447 with a category attached, or 71.6%. Merck accounts for 88.1% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2019 at $4,261 and has fallen 97.1% since, to $124 in 2025.
Across 31 payments — averaging $143.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$4K
- Braintree Laboratories, Inc.$144
- TELA Bio, Inc.$100
- Shire North American Group Inc$71
- Takeda Pharmaceuticals U.S.A., Inc.$33
- Ferring Pharmaceuticals Inc.$28
- plus $152 from 8 others
Across 5 payments — averaging $385.42 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$2K
What the payments were for
- Speaking & faculty fees$3,18572%
- Travel & lodging$60814%
- Food & beverage$65315%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 8 | $3,918 |
| Braintree Laboratories, Inc. | 6 | $144 |
| TELA Bio, Inc. | 1 | $100 |
| Shire North American Group Inc | 4 | $71 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $33 |
| Ferring Pharmaceuticals Inc. | 2 | $28 |
| Davol Inc. | 1 | $28 |
| Novo Nordisk | 1 | $24 |
| Johnson & Johnson | 1 | $19 |
| Pacira Pharmaceuticals Incorporated | 1 | $18 |
| Covidien LP | 1 | $17 |
| THD America, Inc. | 1 | $16 |
| Mallinckrodt Enterprises LLC | 1 | $15 |
| Cook Medical LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,447 in reported general payments places this provider in the 70th percentile of 54 colon & rectal surgery providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LinzessLinaclotide | 11 | $6,650 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 19 | $3,326 |
| Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine | 29 | $1,701 |
| LoperamideLoperamide Hcl | 18 | $1,159 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 15 | $1,013 |
| Hydrocortisone | 74 | $432 |
| Dicyclomine Hcl | 20 | $408 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 22 | $378 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 21 | $271 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 16 | $150 |
| Metronidazole | 20 | $83 |
| Neomycin Sulfate | 13 | $73 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Ferring Pharmaceuticals Inc.Clenpiq | $28 | $3,32619 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 54 colon & rectal surgery providers in Indiana.
Other colon & rectal surgery in Indianapolis
- Shekar NarayananIndianapolis$67K
- Sanjay MohantyIndianapolis$11K
- Nikhil PatelIndianapolis$7K
- Arun GowdamarajanIndianapolis$4K
- Sarah JochumIndianapolis$4K
- Sanjay ThekkeurumbilIndianapolis$3K
- Patrick WhiteIndianapolis$3K
- Ateet ShahIndianapolis$2K
- Bruce RobbIndianapolis$2K
- Peter DavisIndianapolis$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.